MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
ARCA biopharma ROE Ratio 2011-2026 | ABIO
Annual ROE Ratio ARCA biopharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21.9 | -14.42 | -23.82 | -37.85 | -20.93 | -72.04 | -131.48 | -179.79 | -74.18 | -30.06 | -65.73 | -44.54 | -148.61 | -93.58 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -14.42 | -179.79 | -68.49 |
Quarterly ROE Ratio ARCA biopharma
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.49 | -29.63 | 54.27 | 62.67 | 59.73 | 64.34 | -16.18 | -13.78 | -13.66 | -15.37 | -18.6 | -22.1 | -30.4 | -33.27 | -34.17 | -33.56 | -33.46 | -29.41 | -32.53 | -37.33 | -42.42 | -53.33 | -58.43 | -63.52 | -72.1 | -83.31 | -91.89 | -100.46 | -116.63 | -133.36 | -288.63 | -443.89 | -477.14 | -508.09 | -402.23 | -222.28 | -252.34 | -208.31 | -164.28 | -90.19 | -155.92 | -191.58 | -227.25 | -197.18 | -241.72 | -220.53 | -199.33 | -133.61 | -282.21 | -386.28 | -490.36 | -445.82 | -539.4 | -484.37 | -429.35 | -280.74 | -93.58 | -93.58 | -93.58 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 64.34 | -539.4 | -156.6 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Altimmune
ALT
|
-39.17 | $ 3.41 | 2.1 % | $ 300 M |  USA |
 |
Amgen
AMGN
|
89.06 | $ 350.17 | 0.68 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 19.57 | 0.36 % | $ 915 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 217.82 | -1.83 % | $ 5 B |  Danmark |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.4 | 1.82 % | $ 357 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.64 | 1.15 % | $ 16.6 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Benitec Biopharma
BNTC
|
-9.05 | $ 11.0 | 0.18 % | $ 453 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 1.58 | 3.62 % | $ 185 M | USA |
 |
Cellectis S.A.
CLLS
|
-26.25 | $ 3.35 | 0.3 % | $ 116 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-53.8 | $ 12.83 | 0.71 % | $ 773 M | USA |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-1373.04 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-207.61 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-46.05 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
CorMedix
CRMD
|
40.23 | $ 6.29 | 0.64 % | $ 453 K | USA |
 |
CytomX Therapeutics
CTMX
|
-17.54 | $ 4.41 | -1.01 % | $ 608 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
94.87 | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
34.4 | $ 2.12 | 1.2 % | $ 198 M | Israel |
 |
Denali Therapeutics
DNLI
|
-34.38 | $ 20.92 | 3.69 % | $ 3.44 B | USA |
 |
Dyadic International
DYAI
|
-115.6 | $ 0.89 | -5.85 % | $ 25.6 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-68.71 | $ 4.26 | 0.47 % | $ 707 M | Canada |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |